1. Tutto quello che il pediatra dovrebbe sapere sul mepolizumab
- Author
-
Giorgia Carlone, Egidio Barbi, Laura Badina, Antonio Prisco, Massimo Maschio, Prisco, A., Carlone, G., Maschio, M., Badina, L., and Barbi, E.
- Subjects
Churg-Strauss ,mepolizumab ,bambino ,business.industry ,03 medical and health sciences ,0302 clinical medicine ,030228 respiratory system ,Churg-Strau ,Pediatrics, Perinatology and Child Health ,Medicine ,030212 general & internal medicine ,business - Abstract
Mepolizumab, a monoclonal antibody blocking IL-5, is efficacious in the treatment of severe lung diseases sharing eosinophilic inflammation pattern. The paper describes two cases in which the drug was used with excellent results. The first involved a 14-year-old boy with obliterative bronchiolitis, the other an 11-year-old girl with non-atopic asthma. Both cases shared the eosinophilic phenotype of the disease, defined by an eosinophilic count in the peripheral blood equal to or greater than 2% (i.e. a baseline value of 150-200 cells/µl or 300 cells/µl during the previous year). Its use demonstrates clinical improvement in severe refractory asthma with eosinophilic phenotype and as off-label drug in obliterative bronchiolitis, leading to a decrease in the rate of exacerbations and enabling the reduction of corticosteroids as well as the resolution of structural anomalies, respectively.
- Published
- 2021